This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Landiolol
Accession Number
DB12212
Type
Small Molecule
Groups
Investigational
Description

Landiolol has been used in trials studying the treatment of Pharmacokinetics/Dynamics Study.

Structure
Thumb
Synonyms
Not Available
External IDs
AOP-200704 / AOP200704 / LDLL-600 / LDLL600 / ONO-1101
Product Ingredients
IngredientUNIICASInChI Key
Landiolol HydrochlorideG8HQ634Y17144481-98-1DLPGJHSONYLBKP-IKGOIYPNSA-N
Categories
UNII
62NWQ924LH
CAS number
133242-30-5
Weight
Average: 509.6
Monoisotopic: 509.273715228
Chemical Formula
C25H39N3O8
InChI Key
WMDSZGFJQKSLLH-RBBKRZOGSA-N
InChI
InChI=1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22+/m0/s1
IUPAC Name
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-{4-[(2S)-2-hydroxy-3-({2-[(morpholine-4-carbonyl)amino]ethyl}amino)propoxy]phenyl}propanoate
SMILES
CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Landiolol.
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Landiolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Landiolol.
AcebutololThe risk or severity of hyperkalemia can be increased when Acebutolol is combined with Landiolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Landiolol.
AcemetacinAcemetacin may decrease the antihypertensive activities of Landiolol.
AcepromazineLandiolol may increase the orthostatic hypotensive activities of Acepromazine.
AceprometazineAceprometazine may increase the hypotensive activities of Landiolol.
AcetohexamideLandiolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Landiolol is combined with Acetylcholine.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
114905
PubChem Substance
347828494
ChemSpider
102855
ChEBI
135809
ChEMBL
CHEMBL1742466
Wikipedia
Landiolol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
2CompletedDiagnosticCoronary Artery Disease2
2CompletedTreatmentHealthy Volunteers / Pharmacokinetics/Dynamics Study1
2CompletedTreatmentPostoperative Supraventricular Tachyarrythmia1
2, 3CompletedTreatmentPostoperative Supraventricular Tachyarrythmia1
3CompletedDiagnosticCoronary Artery Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.334 mg/mLALOGPS
logP0.44ALOGPS
logP0.35ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.04ChemAxon
pKa (Strongest Basic)8.79ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area127.82 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity131.29 m3·mol-1ChemAxon
Polarizability56.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as morpholine carboxylic acids and derivatives. These are heterocyclic compounds containing a morpholine ring substituted by one or more carboxylic acid groups (or derivative thereof).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Morpholine carboxylic acids and derivatives
Alternative Parents
Phenoxy compounds / Phenol ethers / Ketals / Alkyl aryl ethers / Fatty acid esters / 1,3-dioxolanes / Ureas / Secondary alcohols / 1,2-aminoalcohols / Carboxylic acid esters
show 10 more
Substituents
Morpholine-4-carboxylic acid or derivatives / Phenoxy compound / Phenol ether / Alkyl aryl ether / Ketal / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Benzenoid / Meta-dioxolane
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]
  2. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
  3. Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]

Drug created on October 20, 2016 15:37 / Updated on August 02, 2018 06:35